Mediastinal lymphangioma: Mayo Clinic experience of 25 cases.

Department of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Mayo Clinic Proceedings (Impact Factor: 5.81). 10/2006; 81(9):1197-203. DOI: 10.4065/81.9.1197
Source: PubMed

ABSTRACT To describe the clinical findings, treatment outcomes, disease recurrence rates, and survival of patients with pathologically confirmed mediastinal and cervicomediastinal lymphangioma.
There are 2 patient cohorts. Cohort A consisted of 12 Mayo Clinic patients with pathologically confirmed medilastinal or cervicomediastinal lymphangioma identified from 1986 to 1999. Cohort B consisted of 13 additional patients with mediastinal lymphangioma who had been previously reported from the Mayo Clinic (from 1976 to 1986). All patients were retrospectively identified, and follow-up was performed by either telephone or medical record review.
The mean age at the time of diagnosis was 36.5 years, with a male-female ratio of 1:3. All but 3 patients were symptomatic at presentation, with dyspnea being the most common symptom. Computed tomographic scans commonly revealed a homogeneous, low-attenuation mass that often Involved vascular or airway structures. Although 3 patients were initially observed, all patients had surgical intervention because of symptoms or enlargement of the mass. Thoracotomy with resection was the most common surgical intervention. Five recurrences were noted. Recurrence was minimized by complete excision of the lymphangioma. On follow-up that spanned 23 years, 75% of patients were alive. These survival rates were not statistically different from the expected survival rates of the same age- and sex-matched controls. Only 1 death was attributed to complication from lymphangioma.
Mediastinal and cervicomediastinal lymphangioma are rare lesions that can be treated successfully with surgical excision. Prognosis appears to be excellent because no difference in survival was found between patients and age- and sex-matched controls.

Download full-text


Available from: John Park, Oct 01, 2014
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mediastinal lymphangioma is primarily a benign lesion and the majority of the cases are found incidentally. These lesions account for approximately 1% of all mediastinal tumors. Here we present a giant mediastinal cystic mass in a 35-year-old female who was presented with severe respiratory distress. On the plain chest radiography and CT scan, a massive left pleural effusion with large parasternal and mediastinal lymphadenopathy was seen. Thoracentesis was performed and 400 cm³ of clear fluid was drained from the left hemithorax. However, a subsequent CT scan with contrast and the same technique 40 days later showed a large cystic mass in the mediastinum protruding to the right and left hemi thoraces. The giant cystic mass was resected via right and left anterior thoracotomies. Histopathological examination revealed a diagnosis of lymphangioma. The patient has been alive and without tumor recurrence and has been followed for 2 years.
    Iranian Journal of Medical Sciences 03/2015; 40(2):181-4.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A 34-year-old patient was scheduled for valve replacement to treat a symptomatic mitral regurgitation. The preoperative work-up incidentally discovered an intra-abdominal cystic tumour extending from the epigastrium to the pelvic region on a computed tomography scan. The patient had no abdominal symptoms by the giant cyst from unkown origin. An open "en bloc" resection disclosed a large cyst in the mesocolon. Pathological examination, including immunohistochemistry, enabled the diagnosis of a mesenteric cystic lymphangioma. Long-term follow-up of 12 months shows no recurrence. Mesenteric cystic lymphangioma, which is extremely rare in adults, is a challenge to diagnose and needs complete resection to ensure dignity and to avoid recurrence.
    06/2012; 2012(6):4. DOI:10.1093/jscr/2012.6.4
  • [Show abstract] [Hide abstract]
    ABSTRACT: Many of the thermal runaway accidents that occur in the pharmaceutical industry are due to exothermic secondary reactions. A good understanding of the runaway (e.g., for dynamic modeling purposes) requires knowledge of the stoichiometries of these reactions. A screening test to elucidate the stoichiometries of secondary reactions is presented. It eliminates implausible stoichiometries from a candidate set due to their thermodynamic infeasibility. We use computational chemistry coupled with statistical thermodynamics to estimate the thermodynamic properties of the unfamiliar species typically involved in secondary reactions. The real life runaway of a process to manufacture tetrahydrofurfuryl benzenesulfonate is treated as a case study. Hartree-Fock and Density Functional Theory calculations are performed to test for thermodynamic feasibility, leading to several postulated stoichiometries corresponding to hazardous thermal decomposition.
    Computers & Chemical Engineering 05/1997; DOI:10.1016/S0098-1354(97)87520-5 · 2.45 Impact Factor